Moderate

Chronic hepatitis B management

HBV chronic · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Chronic hepatitis B virus infection (HBsAg positive over 6 months) requires staging of disease phase to decide on nucleos(t)ide antiviral therapy, with lifelong surveillance for cirrhosis and hepatocellular carcinoma. Treatment suppresses viral replication but rarely clears HBsAg.

Red flags

  • Decompensation: ascites, encephalopathy, variceal bleeding
  • Rapid ALT rise/flare
  • New focal liver lesion on imaging
  • Pregnancy with very high viral load (perinatal transmission risk)
  • Hepatitis delta co-infection (accelerated fibrosis)

Assessment

Differential diagnosis

  • Hepatitis B immune-tolerant phase
  • HBeAg-positive or HBeAg-negative chronic hepatitis
  • Inactive carrier (low replicative) state
  • Hepatitis delta co-infection
  • Other chronic liver disease (alcohol, NAFLD, hepatitis C)

Investigations

  • HBsAg, HBeAg/anti-HBe, HBV DNA viral load
  • ALT and liver function tests
  • Hepatitis delta antibody, hepatitis C and HIV co-infection screen
  • Liver fibrosis assessment (transient elastography or fibrosis score)
  • Alpha-fetoprotein and liver ultrasound
  • Renal function and phosphate (for tenofovir choice)

Management

  • Confirm chronicity and determine disease phase using HBV DNA, HBeAg and ALT
  • Assess fibrosis stage with elastography; identify cirrhosis
  • Screen for hepatitis delta, C and HIV co-infection
  • Treat all with cirrhosis, significant fibrosis, or active hepatitis meeting thresholds
  • Start a high-barrier nucleos(t)ide analogue (tenofovir or entecavir)
  • Vaccinate household/sexual contacts and against hepatitis A
  • Give antiviral prophylaxis before immunosuppression/chemotherapy regardless of phase
  • Monitor HBV DNA, ALT and renal function periodically
  • Perform 6-monthly HCC surveillance ultrasound in cirrhosis and selected others
  • Counsel on transmission, alcohol avoidance and adherence
  • Continue therapy long-term; stopping only under specialist guidance
  • Refer pregnant people with high viral load for third-trimester tenofovir

Drugs & doses

Tenofovir disoproxil 245 mg PO once daily
Tenofovir alafenamide 25 mg PO once daily (renal/bone concerns)
Entecavir 0.5 mg PO once daily (1 mg if lamivudine-experienced)
Peginterferon alfa-2a 180 microgram SC weekly for 48 weeks (selected cases)

Disposition

Hepatology/ID outpatient; admit if decompensated; lifelong surveillance.

Complications & pitfalls

  • Cirrhosis and portal hypertension
  • Hepatocellular carcinoma
  • Hepatitis flare on antiviral withdrawal
  • Reactivation during immunosuppression
  • Perinatal/horizontal transmission

Exam pearls

  • Tenofovir and entecavir have high resistance barriers; avoid lamivudine monotherapy
  • Never stop antivirals abruptly in cirrhosis; flares can be fatal
  • Always give prophylaxis before rituximab or chemotherapy in any HBsAg or anti-HBc positive patient
  • Third-trimester tenofovir plus infant vaccine/immunoglobulin prevents vertical transmission
  • HBsAg loss is the functional cure endpoint and is uncommon

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.